However, some clinical concerning issues ABT-199 mw have not been investigated. Methods: we explored the pharmacokinetics and therapeutic efficacy of GX1-rmhTNFα by means of multimodality imaging(SPECT,Bioluminescence imaging, Contrast enhanced ultrasound).TUNEL assay and Immunohistochemistry staining were applied to assess the therapeutic efficacy. Histopathologic examination and biochemistry analysis were also used to assess its side-effects Results: SPECT and biodistribution study revealed specific accumulation of GX1-rmhTNFα in tumors (0.66±0.04%ID/g, 22 times vs. muscle 24h p. i.). BLI, in addition, showed satisfied growth delayed of luciferase expressing

tumors (SGC7901-Fluc) treated with GX1-rmhTNFα in comparison with 0.9 % saline (P<0.001). Postmortem tumor weight also showed a similar tendency (P<0.001). CEUS and CD31 staining demonstrated GX1-rmhTNFα could reduce blood perfusion and induce vascular degradation. TUNEL assay and Ki67 staining indicated pro-apoptosis and anti-proliferation property of GX1-rmhTNFα. Moreover, histopathologic examination and biochemistry analysis indicated limited specific renal or hepatic toxicity of GX1-rmhTNFα. Conclusion: In conclusion, this NVP-LDE225 study demonstrated that GX1-rmhTNFα was a safe and potent anticancer agent, which may have great potential for target therapy of gastric cancer. Key Word(s): 1. Targeted

therapy; 2. Fusion toxin; 3. Gastric cancer; 4. Molecular imaging; Presenting Author: SHUHUI LIANG Additional Authors: XIAOLI HUI, JIAN XU, YANXIANG LV, JING ZHANG, HAO HU, YONGZHAN NIE, BIAOLUO WANG, KAICHUN WU, JIE

DING, DAIMING FAN Corresponding Author: BIAOLUO WANG, KAICHUN WU, JIE DING Affiliations: Xijing Hospital of Digestive Diseases & State Key Laboratory of Cancer Biology; First Affiliate Hospital medchemexpress of Xi’an Jiao Tong University Objective: The vascular-endothelial-cell-specific binding peptide in gastric cancer GEBP11 (CTKNSYLMC) may be a potential candidate for targeted drug delivery in antivascular therapy and diagnosis of gastric cancer. The aim of this study is to further identify the ability of GEBP11 to target the vasculature of gastric cancer in vivo and evaluate the applicability of GEBP11 in neovasculature imaging diagnosis and antiangiogenesis therapy of gastric cancer. Methods: Immunochemical or immunofluorescent staining was performed to identify the subcellular location and the tumor vascular binding specificity of GEBP11. Receptor binding assay was performed to analyze quantitatively the binding specificity and affinity of GEBP11 to ECs. Binding assays in vivo, biodistribution assay and SPECT imaging were used to identify the targeting ability of GEBP11 to tumor tissues in vivo.. BLI or CLI imaging was used for monitoring and evaluation of therapeutic effect in internal radiotherapy experiment.